Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Liabilities
Everything the company owes to creditors and other parties.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 60.8% from a year ago
Total liabilities stood at $26.09M at the end of Q1 FY2026, up 60.8% from a year earlier and down 6.1% from the prior quarter. Over 3 fiscal years it compounded at +31.9% a year.
Context
- Total liabilities amounted to 5.2% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +60.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.78M USD
- Year-over-year change
- +192.2%
- 3-year CAGR
- +31.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.78M | +192.2% |
| FY2024 | 2024-12-31 | 9.51M | -94.7% |
| FY2023 | 2023-12-31 | 181.06M | +1396.6% |
| FY2022 | 2022-12-31 | 12.1M | — |
Total Liabilities vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total liabilities of $26.09M is the 6th highest of the 10 companies compared; the peer median is $32.89M.
- Its year-over-year change of +60.8% is the 3rd highest of 10, against a peer median of +0.2%.
- Total liabilities amounts to 5.2% of total assets for RAPP, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $678.14M | +19.7% | +39.4% | 89.1% | |
| Sep 2026 | $406.66M | -1.7% | +21.6% | 22.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $83.2M | +193.1% | -53.6% | 54.1% |
| Sep 2026 | $52.5M | -0.7% | +15.3% | 4.0% | |
| Mar 2026 | $32.89M | +0.2% | -27.8% | 11.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $26.09M | +60.8% | +31.9% | 5.2% |
| Mar 2026 | $18.95M | +2.1% | +4.5% | 4.5% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $14.79M | +66.9% | -38.6% | 3.8% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $11.31M | -16.2% | +11.3% | 4.3% |
| Mar 2026 | $6.23M | -44.5% | +11.5% | 17.2% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $32.89M | +0.2% | +11.3% | 11.9% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.